Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mavorixafor + axitinib
- Development stage
- Phase 2
- Lead developer
- X4 Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed combination of **mavorixafor**, a selective, orally available CXC chemokine receptor 4 (CXCR4) antagonist, and **axitinib**, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), evaluated in combination therapy for advanced clear cell renal cell carcinoma (ccRCC). **Mavorixafor** blocks CXCR4-mediated signaling, increasing mobilization of neutrophils and lymphocytes, and is FDA-approved for WHIM syndrome. **Axitinib** inhibits angiogenesis by selectively targeting VEGF receptors. The combination is designed to overcome resistance and improve efficacy relative to VEGFR TKI monotherapy in ccRCC; clinical evidence from phase I/II studies indicates improved progression-free survival and objective response rates with manageable safety compared to axitinib alone. The combination is investigational for oncology use[1][4].
- Brand names
- Inlyta (for axitinib)Xolremdi (for mavorixafor)
- Other names
- mavorixafor plus axitinib
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on mavorixafor + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mavorixafor + axitinib.